ANNUAL REPORT 06 - Bosnalijek dd

1% SLOVENIA16% CROATIA31% KOSOVO4% ALBANIA13% SERBIA8% MACEDONIA27% MONTENEGROIn this market area, Bosnalijek has accomplished increase of sale of 40%in relation to previous year and kept the highest share of this region inthe structure of total export, with tendency of its mild lowering due toa greater increase of sale in countries of other regions.Ex-YU and Albania regionIn this market area, Bosnalijek has accomplished increase of sale of 40%in relation to previous year and kept the highest share of this region in thestructure of total export, with tendency of its mild lowering due to agreater increase of sale in countries of other regions.At markets of Ex-YU and Albania, Bosnalijek shall build an image of arenowned pharmaceutical producer with well introduced and qualitativeproducts, of recognisable brands.• A 22% increase of sale was realised in Montenegro, good marketposition was strengthened with recognisability of Bosnalijek brands.• Sale in Croatia was increased by three times in relation to year 2005,activities were realised on registration of new products and verysuccessful cooperation was continued with Jadran GalenicLaboratory from Rijeka.• Macedonia market, with very low prices and dominant monopolisticposition of domestic producers, has required organisational and staffchanges in representative office, forming of new team of workers andnew marketing strategy directed at commercial sale and„non-prescription“ medicines.• In Serbia, increase of sale of 67% was realised with intensive work ofexpert associates and a significant advancement in prescribing of ourmedications. Representative office started working in 2006, and newwholesalers were introduced into distribution, by which availabilityof our portfolio at total market was raised to a satisfactory level.• Increase of sale in Albania of 30% was realised, a greater number ofproducts was registered, the work of expert associates was establishedin the field, and intensive promotional activities commenced for Lopril®,Lopril®H, Rhinostop®, Enterofuryl® etc.• With continuous increase of sale at Kosova, Bosnalijek has gained imageof a reliable producer of highly qualitative medicines and strengthenedthe market position.Lopril®, Lopril®H, Ulcosan®,Rhinostop®, Pilfud®, Royal Jelly®and otherB osnalijek produc ts at this market have become quite demanded since theygained trust of both doc tors and patients with their qualit y and efficac y.serving Your health INTERNATIONAL MARKETS ANNUAL REPORT 06 27